Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas

Molecular Cancer Therapeutics

Volumn 8, Issue 11, 2009, Pages 3024-3035

  Hu, Kaiji ^a   Lee, Cathy ^a   Qiu, Dexin ^a   Fotovati, Abbas ^a   Davies, Alastair ^a   Abu Ali, Samah ^a   Wai, Daniel ^b   Lawlor, Elizabeth R ^b   Triche, Timothy J ^b   Pallen, Catherine J ^a   Dunn, Sandra E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIN B1; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATASE; PHOSPHOTRANSFERASE; POLO LIKE KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WEE1 KINASE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; EWING SARCOMA; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; UNINDEXED SEQUENCE;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; GENE SILENCING; GENE THERAPY; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; MICE; NEUROBLASTOMA; OSTEOSARCOMA; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RHABDOMYOSARCOMA; RNA, SMALL INTERFERING; SARCOMA, EWING'S; TRANSFECTION;

EID: 70949085635     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0365     Document Type: Article

References (50)

1. Paulino AC, Okcu MF. Rhabdomyosarcoma. Curr Probl Cancer 2008;32:7-34.
2. Merlino G, Helman LJ. Rhabdomyosarcoma-working out the pathways. Oncogene 1999;18:5340-5348
3. Pappo AS, Shapiro DN, Crist WM, Maurer HM. Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 1995;13:2123-2139
4. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006;66:6936-6946 (Pubitemid 44197668)
5. Kurmasheva RT, Houghton PJ. Pediatric oncology. Curr Opin Chem Biol 2007;11:424-432
6. Blandford MC, Barr GC, Lynch JC, Randall RL, Qualman SJ, Keller C. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group. Pediatr Blood Cancer 2006;46:329-338 (Pubitemid 43201849)
7. Melcon SG, de Toledo Codina JS. Molecular biology of rhabdomyosarcoma. Clin Transl Oncol 2007;9:415-419
8. Scrable HJ, Witte DP, Lampkin BC, Cavenee WK. Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. Nature 1987;329:645-647
9. Barr FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997;19:483-491
10. Bennicelli JL, Fredericks WJ, Wilson RB, Rauscher FJ III, Barr FG. Wild-type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene 1995;11:119-130
11. Fredericks WJ, Galili N, Mukhopadhyay S, et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcoma is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995;15:1522-1535
12. Khan J, Wei JS, Ringner M, et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001;7:673-679 (Pubitemid 32588022)
13. Baer C, Nees M, Breit S, et al. Profiling and functional annotation of mRNA gene expression in pediatric rhabdomyosarcoma and Ewing's sarcoma. Int J Cancer 2004;110:687-694 (Pubitemid 38746027)
14. Wachtel M, Dettling M, Koscielniak E, et al. Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2) (q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 2004;64:5539-5545 (Pubitemid 39095545)
15. De Pittà C, Tombolan L, Albiero G, et al. Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3-FKHR positive and negative tumors. Int J Cancer 2006;118:2772-2781 (Pubitemid 43673356)
16. Schaaf GJ, Ruijter JM, van Ruissen F, et al. Full transcriptome analysis of rhabdomyosarcoma, normal, and fetal skeletal muscle: statistical comparison of multiple SAGE libraries. FASEB J 2005;19:404-406
17. Goldstein M, Meller I, Issakov J, Orr-Urtreger A. Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. Neoplasia 2006;8:332-343 (Pubitemid 43830740)
18. Ebauer M, Wachtel M, Niggli FK, Schafer BW. Comparative expression profiling identifies an in vivo target gene signature with TFAP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 2007;26:7267-7281 (Pubitemid 350085317)
19. Romualdi C, De Pittà C, Tombolan L, et al. Defining the gene expression signature of rhabdomyosarcoma by meta-analysis. BMC Genomics 2006;7:287-302. (Pubitemid 44774166)
20. Ren YX, Finckenstein FG, Abdueva DA, et al. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations. Cancer Res 2008;68:6587-6597
21. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005;7:591-600.
22. Saab R, Bills JL, Miceli AP, et al. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells. Mol Cancer Ther 2006;5:1299-1308
23. Amstutz R, Wachtel M, Troxler H, et al. Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Res 2008;68:3767-3776
24. Cao L, Yu Y, Darko I, et al. Addiction of elevated insulin-like growth factor I receptor and initial modulation of the AKT pathway define the responsiveness of rhabdomyosarcoma to the targeting antibody. Cancer Res 2008;68:8039-8048
25. Cen L, Arnoczky KJ, Hsieh FC, et al. Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod Pathol 2007;20:936-946
26. To K, Zhao Y, Jiang H, et al. The phosphoinositide-dependent kinase-1 inhibitor, OSU-03012, prevents Y-box binding protein-1 (YB-1) from inducing epidermal growth factor receptor (EGFR). Mol Pharmacol 2007;72:641-652
27. Lee C, Dhillon J, Wang MY, et al. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 2008;68:8661-8666
28. Newton WA Jr., Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification - an intergroup rhabdomyosarcoma study. Cancer 1995;76:1073-1085
29. Santos ND, Habibi G, Wang M, et al. Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK). Translational Oncogenomics 2007;2:67-79.
30. Davicioni E, Anderson MJ, Finckenstein FG, et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group. Am J Pathol 2009;174:550-564
31. Taniguchi E, Nishijo K, McCleish AT, et al. PDGFR-A is a therapeutic target in alveolar rhabdomyosarcoma. Oncogene 2008;27:6550-6560
32. Wan X, Shen N, Mendoza A, Khanna C, Helman LJ. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked tothe targeting of mTOR/Hif-1α/VEGF signaling. Neoplasia 2006;8:394-401.
33. Chen CL, Loy A, Cen L, et al. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells. BMC Cancer 2007;7:111-120
34. Petricoin EF, Espina V, Araujo RP, et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007;67:3431-3440
35. Elia U, Flescher E. PI3K/Akt pathway activation attenuates the cytotoxic effect of methyl jasmonate toward sarcoma cells. Neoplasia 2008;10:1303-1313
36. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-330
37. Perez de Castro I, de Carcer G, Malumbres M. A census of mitotic cancer genes: new insight into tumor cell biology and cancer therapy. Carcionogenesis 2007;28:899-912.
38. Perez de Castro I, de Carcer1 G, Montoya G, Malumbres M. Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. Curr Opin Pharmacol 2008;8:375-383
39. Reindl W, Yuna J, Kramer A, Strebhardt K, Berg T. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 2008;15:459-466
40. Liu X, Erikson R. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 2003;100:5789-5794 (Pubitemid 36576886)
41. Liu X, Lei M, Erikson R. Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 2006;26:2093-2108 (Pubitemid 43346913)
42. Toyoshima-Morimoto F, Taniguchi E, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002;3:341-348 (Pubitemid 34467604)
43. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001;410:215-220 (Pubitemid 32216594)
44. Reagan-Shaw S, Ahmad N. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer. FASEB J 2005;19:611-613 (Pubitemid 40471261)
45. Bu Y, Yang Z, Li Q, Song F. Silencing of polo-like (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells. Oncology 2008;74:198-206.
46. Feng Y, Lin D, Shi Z, et al. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int J Cancer 2009;124:578-588
47. Olmos D, Swanton C, de Bono J. Targeting polo-like kinase: learning too little and too late?. J Clinical Oncol 2008;26:5497-5499
48. Taylor A, Shu L, Danks M, et al. p53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines. Med Pediatr Oncol 2000;35:96-103.
49. Caldas H, Holloway MP, Hall BM, Qualman SJ, Altura RA. Survivin-directed RNA interference cocktail is a potent suppressor of tumour growth in vivo. J Med Genet 2006;43:119-128
50. Ikezoe T, Yang J, Nishioka C, et al. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies. Leukemia 2009Vol nr:23:1564-1576